Mercy Gynecologic Oncologist, Dr. Beman Khulpateea, Discusses Research Connecting HPV Vaccine to Reduction in Cervical Cancer
January 04, 2021
A new study shows the HPV vaccine is curbing cervical cancer risk.
Published in the New England Journal of Medicine, the study found there is a significant decrease in cervical cancer patients who have received the HPV vaccine compared to those who did not.
The vaccine was developed in 2006. According to Fellowship-trained Mercy gynecologic oncologist Dr. Beman Khulpateea, the study finally puts together years of data.
"One of the things the study pointed out was the benefit of early vaccination, so people who get a vaccine at an early age -- both girls and boys -- have a lower risk of developing subsequent disease," Dr. Khulpateea said.
In the United States, doctors recommend starting HPV vaccinations at 11 or 12 years old.
Dr. Khulpateea sees patients at The Gynecologic Oncology Center at Mercy, one of Baltimore's leading centers in GYN cancers. He provides diagnosis and treatment for gynecologic disease including ovarian, uterine, cervical and vulvar cancers.
About Mercy
Founded in 1874 in Downtown Baltimore by the Sisters of Mercy, Mercy Medical Center is a 183-licensed bed, acute care, university-affiliated teaching hospital. Mercy has been recognized as a high-performing Maryland hospital (U.S. News & World Report); has achieved an overall 5-Star quality, safety, and patient experience rating (Centers for Medicare and Medicaid Services); is A-rated for Hospital Safety (Leapfrog Hospital Safety Grade); and is certified by the American Nurses Credentialing Center as a Magnet™ hospital. Mercy Health Services is a not-for-profit health system and the parent company of Mercy Medical Center and Mercy Personal Physicians.
Media Contact
Dan Collins, Senior Director of Media Relations
Office: 410-332-9714
Cell: 410-375-7342
Email: dcollins@mdmercy.com